Johnson & Johnson (JNJ) Earnings Date & Reports
Johnson & Johnson is the world's largest and most diverse healthcare firm... Show more
JNJ is expected to report earnings to rise 5.56% to $2.85 per share on July 15
Johnson & Johnson (JNJ) Q1 2026 Earnings Recap: Revenue Beats and Raised Guidance
Key Takeaways
- Johnson & Johnson reported Q1 2026 sales of $24.1 billion, up 9.9% on a reported basis and beating consensus estimates around $23.6 billion.
- Adjusted diluted earnings per share (EPS) came in at $2.70, surpassing analyst expectations of $2.67 to $2.68.
- Innovative Medicine sales grew 7.4% operationally to $15.4 billion, driven by oncology; MedTech up 4.6% to $8.6 billion.
- Company raised full-year 2026 guidance, now expecting operational sales growth of 5.6%–6.6% and adjusted operational EPS of $11.30–$11.50.
- Multiple product approvals highlight pipeline strength amid ongoing STELARA biosimilar pressures.
- Post-earnings stock reaction was muted, with shares slightly lower despite the beats.
Earnings Context and Why It Matters
Johnson & Johnson, a healthcare powerhouse focused on Innovative Medicine and MedTech following the Kenvue consumer spin-off, kicked off 2026 with solid Q1 results. This report is pivotal for investors tracking the company's transition to high-growth pharma and devices amid patent cliffs like STELARA (ustekinumab) biosimilars and talc litigation resolutions. Strong oncology demand and new approvals underscore pipeline durability, while MedTech recovery signals procedural volume rebounds. For dividend aristocrats and long-term holders, these figures affirm sustainable growth in a sector facing regulatory and competitive headwinds, influencing sector ETFs and healthcare allocations.
Johnson & Johnson posted first-quarter 2026 sales of $24.1 billion, reflecting 9.9% reported growth, 6.4% operational growth (excluding currency impacts), and 5.3% adjusted operational growth from the prior year. This topped consensus revenue forecasts of approximately $23.6 billion.
Adjusted diluted EPS reached $2.70, exceeding Wall Street's $2.67–$2.68 consensus, while GAAP EPS was $2.14. Innovative Medicine drove momentum with $15.4 billion in sales (7.4% operational growth), led by oncology up 17.8% operationally on DARVYKTI and CARVYKTI gains, offsetting immunology declines from STELARA biosimilars. MedTech contributed $8.6 billion (4.6% operational), boosted by cardiovascular (10.5%) but tempered in surgery.
The company updated 2026 guidance upward: operational sales growth to 5.6%–6.6% (midpoint 6.1%), with adjusted operational EPS of $11.30–$11.50 (midpoint $11.40), signaling confidence in pipeline execution.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock discovery process.
Market Reaction and Investor Sentiment
Despite beating Q1 estimates and raising guidance, JNJ shares saw a muted market reaction, trading slightly lower in the days following the April 14 release amid broader market volatility and tempered expectations for aggressive upside. Investor sentiment remains constructive, with analysts citing oncology momentum and pipeline wins as positives, though STELARA erosion (~200 bps drag expected ongoing) tempers enthusiasm. Price targets from firms like Barclays ($255) and Morgan Stanley ($267) reflect optimism for steady execution.+Opinions+on+Q1+Earnings+Release)
Forward Outlook and Key Factors to Monitor
Investors should track guidance execution, with H1 and H2 growth projected evenly, focusing on Innovative Medicine's ability to offset STELARA biosimilar losses through oncology (DARZALEX family, CARVYKTI) and neuroscience ramps.
In MedTech, cardiovascular and orthopaedics launches offer upside, but surgery margins bear watching amid volume contracts and competition. Recent approvals like ICOTYDE for psoriasis and TECVAYLI combos for myeloma bolster the pipeline, potentially driving long-term revenue.
Upcoming catalysts include the Enterprise Business Review on December 8, 2026, detailing strategic priorities. Broader factors: free cash flow (~$1.5B in Q1 for dividends/buybacks), interest expense trends, and U.S./international demand signals. Talc resolutions provide tailwinds, but in-process R&D impairments signal execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor